钙剂治疗高钾血症的有益效应并非源于「膜稳定作用」
该研究在犬心室楔形组织(n=7)和分离心肌细胞上记录光学动作电位与容积平均心电图,比较基线(钾 4 mM)、高钾血症(8–12 mM)及高钾+钙(3.6 mM)状态。高钾使传导速度降低 67%±7%(p<0.001)、动作电位时程均匀缩短 20%±10%(p<0.002),导致 QRS 增宽和「正弦波」图形;钙治疗使传导速度恢复 44%±18%(p<0.02)、QRS 变窄、心电图正常化,但未恢复动作电位时程。高钾升高静息膜电位而钙治疗未恢复之,且钙效应在 L 型钙通道阻滞时减弱,提示钙依赖性传导机制而非膜稳定。作者认为高钾血症引起传导异常(即 QRS 延长)时,钙治疗有机制上的合理性。
要点
- 犬心室楔形组织(n=7)中,高钾血症(8–12 mM)使传导速度降低 67%±7%(p<0.001),动作电位时程缩短 20%±10%(p<0.002),出现 QRS 增宽与「正弦波」图形。
- 钙治疗(3.6 mM)使传导速度恢复 44%±18%(p<0.02)、QRS 变窄、心电图正常化,但未恢复动作电位时程。
- 高钾血症升高静息膜电位,钙治疗未使其恢复,提示效应不依赖「膜稳定」。
- L 型钙通道阻滞时钙的效应减弱,提示机制与钙依赖性(而非通常的钠依赖性)传导有关。
- 作者认为,高钾血症产生传导异常(即 QRS 延长)时,钙治疗有机制上的合理性。
适用人群与场景
- 犬心肌细胞与组织制备(心室楔形组织 n=7),为实验室研究,非患者人群。
诊断标准与关键阈值
- 基线钾浓度 4 mM;高钾血症 8–12 mM;高钾+钙时钙浓度 3.6 mM;分离心肌细胞高钾 8 mM、钙治疗 6 mM。
研究设计与关键结果
- 研究类型:对照实验试验,实验室研究,犬心肌细胞与组织制备;心室楔形组织 n=7。
- 高钾血症使传导速度降低 67%±7%(p<0.001),动作电位时程均匀缩短 20%±10%(p<0.002),导致 QRS 增宽和严重高钾血症的「正弦波」图形。
- 钙治疗使传导速度恢复 44%±18%(p<0.02),QRS 变窄、心电图正常化,但未恢复动作电位时程。
- 高钾血症显著升高静息膜电位,钙治疗未使其恢复;L 型钙通道阻滞时钙的效应减弱。
证据类型、等级与局限
- 证据类型:对照实验试验(实验室研究,犬心肌细胞与组织制备)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,高钾血症引起传导异常(即 QRS 延长)时,钙治疗有机制上的合理性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Hyperkalemia is a common life-threatening condition causing severe electrophysiologic derangements and arrhythmias. The beneficial effects of calcium (Ca 2+ ) treatment for hyperkalemia have been attributed to "membrane stabilization," by restoration of resting membrane potential (RMP). However, the underlying mechanisms remain poorly understood. Our objective was to investigate the mechanisms underlying adverse electrophysiologic effects of hyperkalemia and the therapeutic effects of Ca 2+ treatment.
DESIGN: Controlled experimental trial.
SETTING: Laboratory investigation.
SUBJECTS: Canine myocytes and tissue preparations.
INTERVENTIONS AND MEASUREMENTS: Optical action potentials and volume averaged electrocardiograms were recorded from the transmural wall of ventricular wedge preparations ( n = 7) at baseline (4 mM potassium), hyperkalemia (8-12 mM), and hyperkalemia + Ca 2+ (3.6 mM). Isolated myocytes were studied during hyperkalemia (8 mM) and after Ca 2+ treatment (6 mM) to determine cellular RMP.
MAIN RESULTS: Hyperkalemia markedly slowed conduction velocity (CV, by 67% ± 7%; p < 0.001) and homogeneously shortened action potential duration (APD, by 20% ± 10%; p < 0.002). In all preparations, this resulted in QRS widening and the "sine wave" pattern observed in severe hyperkalemia. Ca 2+ treatment restored CV (increase by 44% ± 18%; p < 0.02), resulting in narrowing of the QRS and normalization of the electrocardiogram, but did not restore APD. RMP was significantly elevated by hyperkalemia; however, it was not restored with Ca 2+ treatment suggesting a mechanism unrelated to "membrane stabilization." In addition, the effect of Ca 2+ was attenuated during L-type Ca 2+ channel blockade, suggesting a mechanism related to Ca 2+ -dependent (rather than normally sodium-dependent) conduction.
CONCLUSIONS: These data suggest that Ca 2+ treatment for hyperkalemia restores conduction through Ca 2+ -dependent propagation, rather than restoration of membrane potential or "membrane stabilization." Our findings provide a mechanistic rationale for Ca 2+ treatment when hyperkalemia produces abnormalities of conduction (i.e., QRS prolongation).
参考来源
- Piktel JS, Wan X, Kouk S, et al. Beneficial Effect of Calcium Treatment for Hyperkalemia Is Not Due to "Membrane Stabilization". Crit Care Med. 2024. PMID: 39046789. doi:10.1097/CCM.0000000000006376
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。